Health
ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
TOKYO & BASKING RIDGE, N.J., October 01, 2025--ENHERTU Followed by THP sBLA Accepted in the U.S. for Patients with High-Risk HER2+ Early Breast Cancer Prior to Surgery
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/030f124cb64848e25381e71558eba0e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3D1tIMbTLkcwa84t.jy2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/030f124cb64848e25381e71558eba0e0","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on results from DESTINY-Breast11, the first phase 3 trial to demonstrate benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in early-stage breast cancer","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"If approved, ENHERTU followed by THP could represent a new treatment approach prior to surgery in this setting","length":110,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":269,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 01, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) has been accepted for review in the U.S. for the neoadjuvant treatment of adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer.","length":447,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.","length":195,"tagName":"p"},{"type":"text","content":"The acceptance is based on results from the DESTINY-Breast11 phase 3 trial, which showed that ENHERTU followed by THP demonstrated a statistically significant and clinically meaningful improvement in pathologic compete response (pCR) rate along with an improved safety profile compared to dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used prior to surgery for patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Data from the trial also showed an early positive trend in event-free survival (EFS) favoring ENHERTU followed by THP c...